Last reviewed · How we verify
Biological: Experimental: Tezepelumab
Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine in type 2 inflammation.
Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine in type 2 inflammation. Used for Moderate-to-severe asthma (type 2 inflammation), Atopic dermatitis.
At a glance
| Generic name | Biological: Experimental: Tezepelumab |
|---|---|
| Also known as | Tezepelumab |
| Sponsor | AstraZeneca |
| Drug class | TSLP antagonist monoclonal antibody |
| Target | TSLP (Thymic Stromal Lymphopoietin) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Respiratory / Dermatology |
| Phase | Phase 3 |
Mechanism of action
TSLP is an epithelial-derived cytokine that activates dendritic cells and promotes T helper 2 (Th2) cell differentiation, driving type 2 inflammatory responses. By neutralizing TSLP, tezepelumab suppresses the cascade of type 2 cytokines (IL-4, IL-5, IL-13) and reduces eosinophil activation, mast cell degranulation, and IgE production. This upstream mechanism addresses multiple type 2 inflammatory diseases including asthma and atopic dermatitis.
Approved indications
- Moderate-to-severe asthma (type 2 inflammation)
- Atopic dermatitis
Common side effects
- Headache
- Nasopharyngitis
- Injection site reactions
Key clinical trials
- Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological: Experimental: Tezepelumab CI brief — competitive landscape report
- Biological: Experimental: Tezepelumab updates RSS · CI watch RSS
- AstraZeneca portfolio CI